A total of 201 critically ill patients were studied during 267 courses of gentamicin or tobramycin treatment (139 gentamicin courses and 128 tobramycin courses). Of these 267 courses, pharmacokinetic and clinical data were obtained for 240 (120 gentamicin and 120 tobramycin). The data collected for pharmacokinetic analysis included measurements of serial blood and urine levels, urinary excretion of fl2-microglobulin, protein levels, and granular casts. A two-compartment model was used to assess tissue accumulation, and in 89 courses the predicted accumulation was confirmed by cumulative urine collection or postmortem tissue analysis. As groups, the patients given gentamicin and tobramycin did not differ in age, weight, creatinine clearance, total dose given, duration of treatment, initial aminoglycoside trough serum levels, number of dosage adjustments, concurrent use of furosemide, or concurrent cephalosporins. Previous aminoglycoside treatment (usually gentamicin) had occurred more frequently in the tobramycintreated patients (P < 0.01), and more males than females received tobramycin (P < 0.05). Pharmnacokinetic assessments of renal damage were based on both changes in glomerular filtration rate (serum creatinine levels, creatinine clearance) and renal tubular damage (,82-microglobin, casts), but only patients with elevated aminoglycoside tissue levels leading to renal tubular damage and subsequent creatinine clearance decreases were considered to have experienced aminoglycoside nephrotoxicity. In the pharnacokinetic analysis of nephrotoxicity, 29 gentamicin courses (24%) and 12 tobramycin courses (10%) were complicated by nephrotoxicity (P < 0.01). The 201 study patients were also evaluated independently for clinical nephrotoxicity (defined as a serum creatinine level increase of 0.5 mg/dl or more). Clinical nephrotoxicity occurred at rates of 37% in the gentamicin-treated group and 22% in the tobramycin-treated group (P < 0.02). In these similar groups of critically ill patients, tobramycin was less nephrotoxic than gentamicin.
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Aminoglycoside antibiotics are potentially nephrotoxic substances which may cause specific damage to the lining cells of renal proximal tubules. The incidence of reported nephrotoxic damage in aminoglycoside-treated patients has increased from 5 to almost 40% recently (2, 4, 7, 8, 19) ; the occurrence rate is apparently a function of the type of patients studied, variations in the methods used to define nephrotoxicity, and intensity of renal monitoring by investigators.
The incidence of nephrotoxicity may also vary with the aminoglycoside used. Animal studies readily differentiate these compounds. Gentamicin is more nephrotoxic than tobramycin, netilmicin, or amikacin in animals (3, 5, 6) . In animal studies elevated aminoglycoside doses are used, which result in blood levels that markedly exceed the levels employed to treat human infections. Also, at least one compound must produce nephrotoxicity in most study animals, so that these animals can serve as a reference population for comparing aminoglycosides. In human trials, nephrotoxicity is much less common, and it may occur for different reasons than overdoses.
The widespread clinical use of dosing nomograms and the monitoring of serum concentrations mean that both overdoses and elevated blood concentrations are avoided, yet nephrotoxicity still occurs (1, 2, 7, 16, 18, 19) . Thus, animals are overdosed until renal failure occurs, whereas patients may experience renal damage despite the use of recommended doses and therapeutic serum concentrations (1, 2, 15, 16, 18) . In view of the differences between the nephrotoxic damage produced by overdoses in animals and clinical aminoglycoside nephrotoxicity, comparative studies in animals may x; t provide relevant models for characterization of comparative clinical nephrotoxicity. Furthermore, the belief that aminoglycoside nephrotoxicity is always dose related might also be challenged, since clinical nephrotoxicity has not been abolished by the use of proper doses.
Our pharmacokinetic studies in patients have provided some insight into the pathogenesis of renal damage when appropriate doses are used. An early finding of these studies was that abnormally high aminoglycoside accumulations in renal tissue lead to proximal tubular damage, even though aminoglycoside blood levels remain normal (9, 15) . A characteristic pattem of renal tubular damage precedes an eventual increase in serum creatinine levels by 5 to 10 days (15) . In the patients experiencing aminoglycoside nephrotoxicity, increases in serum creatinine levels occur late in the sequence of events, after evidence of abnormally rapid tissue accumulation and proximal damage, as measured by urine sediment changes and excretion of f32-microglobulin (14) . Thus, an increase in the serum creatinine level may reflect damage to the proximal tubules which actually began 5 to 7 days before changes in glomerular filtration.
We applied these criteria to a study of the comparative nephrotoxicities of gentamicin and tobramycin. Our study involved two groups from a homogeneous population of acutely ill older patients having similar base-line risks for nephrotoxicity and similar clinical complications during hospitalization.
MATERIALS AND METHODS
Patients. A total of 201 acutely ill patients were given 267 courses of aminoglycoside therapy (139 gentamicin courses, 128 tobramycin courses). These patients were older adults (average age, 66 years) with serious infections complicating either major medical or surgical disorders. All but a few of these patients had abdominal infections, pneumonia, septicemia, or a combination of these diseases. Each was entered prospectively into the study at the time of request for therapy and pharmacokinetic monitoring, after gentamicin or tobramycin was selected for use by the attending physician. The rates of patient accession were similar for the gentamicin-treated and tobramycin-treated groups over the 2-year study period.
Doses and sample collection. Rates of aminoglycoside administration were determined individually for all patients according to nomograms and measured peak and trough serum concentrations. Blood for assays was obtained throughout treatment and in most patients for 10 to 20 days after aminoglycoside treatment was stopped (to quantitate the terminal halflife), as previously described (9, 10, (11) (12) (13) 15 Assays. Serum, urine, and postmortem tissue aminoglycoside concentrations were measured by both a microbiological assay and a radioimmunoassay, as previously described (12, 13) . The lower limit of sensitivity for the radioimmunoassay was 0.03 pg/ml; thus, this assay allowed measurement of both serum and urine concentrations for 10 to 30 days after the last dose. Serum creatinine levels and 24-h creatinine clearance values were determined by autoanalyzer methods; 24-h urinary excretion of 82-microglobulin was determined by the radioimmunoassay, and values of more than 50 mg/24 h were associated with nephrotoxicity (4) . Quantitative cast counts were performed daily on random urine samples, and values of more than 500 casts per mil on 3 consecutive days were associated with nephrotoxicity (10 (15) . The second criterion of the pharmacokinetic assessment was an increase in urine ,I2-microglobin levels and casts occurring before the serum creatinine level increase in a specific pattern, as previously described (15) . In the pharmacokinetic definition of nephrotoxicity, serum creatinine level increases of more than 0.5 mg/dl not preceded by indices of renal tubular damage or abnormal tissue accumulation were considered to be caused by something other than aminoglycoside nephrotoxicity (15) .
Anlalysis. Each course of aminoglycoside therapy was examined separately even in the same patient, since clinical status and risk factors could change course by course. About 25% of the patients were studied during more than one course of therapy. A separate analysis of only those single-course patients who had not received aminoglycosides prevously examined the influence ofprevious aminoglycoside treatments on our findings. Differences between aminoglycosides were analyzed by using the Student t test and the chi-square test with the Yates correction. A P value of <0.05 was considered significant.
RESULTS
Of the 267 courses of treatment examined, 9 were excluded from the clinical analysis, either because of failure to determine serum creatinine levels after therapy or because hemodialysis invalidated serial creatinine level measurements. The remaining 258 courses were analyzed by using clinical criteria.
Of the 267 courses, 27 were excluded from the pharmacokinetic analysis because there were inadequate data to employ the pharmacokinetic criteria for nephrotoxicity. Of the remaining 240 courses, 120 patients were given gentamicin and 120 received tobramycin. This report summarizes our findings after an analysis of these 240 courses of treatment by using the pharmacokinetic criteria for nephrotoxicity and compares the incidence of nephrotoxicity as determined by pharmacokinetic assessment with the incidence as determined by clinical criteria.
Analysis of course eliminated due to insufficient pharmacokinetic data. A total of 27 courses had inadequate data for analysis by the pharnacokinetic criteria, but all 27 could be evaluated for creatinine level increases. Of these 27 courses, 19 involved gentamicin and 8 involved tobramycin. Creatinine level increases occurred in 3 of 19 gentamicin courses and in 3 of 8 tobramycin courses. If all six of these creatinine level increases had been caused by the aminoglycosides, the outcome of this study regarding gentamicin and tobramycin nephrotoxicities would not have changed (X2 = 5.2; P < 0.02).
Nephrotoxicity in 240 courses as determined by pharmacokinetic analysis. The 120 gentamicin and 120 tobramycin courses of treatment were administered to patients of simnilar age, weight, initial creatinine clearance level and incidence ofproven infection (Table 1) . Onefourth of each group had positive blood cultures. Previous aminoglycoside treatments (usually with gentamicin) were given twice as frequently to the tobramycin group (P < 0.001), and more men than women were given tobramycin (P < 0.05).
During treatment, the two groups had similar initial trough concentrations, received the same average doses and durations of treatment, and required an average of 1.1 dosage changes (usually decreases) to maintain blood levels within the therapeutic range. Cephalosporins were given concurrently in slightly more tobramycin courses, and diuretics (chiefly furosemide) were given in more gentamicin courses ( Table 1) . Neither of these differences was significant.
About 75% of the infections in each group either were cured or improved by the treatment (Table 2 ). Approximately 25% of the patients in each group died, usually as a consequence of an underlying disease. However, in 11 of the patients (4.5%) who died aminoglycoside-induced renal failure was a major contributing factor.
By the end of therapy, the gentamicin-treated group had a greater mean decrease in creatinine clearance (P < 0.02), a higher final trough concentration (P < 0.05), and a greater average tissue accumulation (P < 0.01) than the tobramycin-treated group (Table 2 ). Figure 1 shows the measured tissue accumulation values and the values predicted in the patients for whom we obtained consent for autopsy. This figure shows that the pharmnacokinetic model was accurate for both gentamicin and tobramycin over the entire range of the observed tissue accumulation values. Consistent with differences between gentamicin and tobramycin in tissue accumulation, nephrotoxicity occurred in 24% of the gentamicin courses and in 10% of the tobramycin courses, a significant difference (P < 0.01).
Comparative nephrotoxicities as determined by pharmacokinetic assessment and clinical criteria. Clinical criteria identified nephrotoxicity in 37% of the gentamicin courses and 22% of the tobramycin courses (P < 0.02).
As nearly all patients with creatinine level increases were defined clinically as experiencing aminoglycoside nephrotoxicity, clinical nephrotoxicity occurred more often than pharmacokinetic nephrotoxicity, the latter requiring abnormal tissue accumulation and evidence of tubular damage before creatinine level increases. Pharmacokinetic assessments, which were based primarily on abnormal tissue accumulation, attrib- c Difference between gentamicin-treated group and tobramycin-treated group significant at P < 0.02.
d The value on the last day of treatment. The difference between the gentamicin-trea,ted group and the tobramycin-treated group was significant at P < 0.05. ' Calculations were based on a two-compartment pharmacokinetic model and were confirmed independently by urine or postmortem tissue measurements for 81 courses of treatment.
f Difference between gentamicin-treated group and tobramycin-treated group significant at P < 0.01. 9 These values were based on 258 courses (137 gentamicin, 121 tobramycin) because serum creatinine levels were available for 18 more courses than complete pharmacokinetic assessments (120 gentamicin, 120 tobramycin).
h Mean ± standard deviation. Single-course analysis. Table 4 shows the results of a single-course analysis which was perforned to examine the influence of both previous and multiple-course treatments. Beginning with the 240 courses, we excluded all patients who had more than one course of aminoglycoside treatment and all patients who had received aminoglycosides previously, whether or not we had studied them during the previous course of treatment.. Of the 136 patients remaining, 56 received tobramycin, and 80 were given gentamicin. In these patients, the population characteristics were similar to those shown in Table 1 Finally, the results of a double-blind randomized comparative trial in which nephrotoxicity was defined by serum creatinine level increases also agreed with our pharmacokinetic assessment that gentamicin was more nephrotoxic than tobramycin (17) . The two studies were complimentary, as our findings support the use of serum creatinine levels in less acutely ill patients, such as those employed in this double-blind trial, whereas the conclusion that gentamicin is more nephrotoxic than tobramycin in a study designed to be free of interpretive bias lends further support to the utility of the pharnacokinetic assessment of nephrotoxicity in severely ill patients.
In a group of critically ill patients, the use of the pharmacokinetic criteria lowers the overall incidence of nephrotoxicity attributable to both gentamicin and tobramycin, perhaps because these criteria more reliably distinguish the nephrotoxic potential of these agents in a manner consistent with the known pathogenesis of aminoglycoside renal damage. However, the absolute specificity of the pharmacokinetic criteria can only be determined when there is a group of infected patients at equal risk not given aminoglycosides, an impossible study design until nonnephrotoxic alternatives to aminoglycosides become available.
In our 240 courses of treatment, there can be no doubt that older age, concurrent disease, critically ill status, and concurrent multiple-drug treatments combined to produce an extremely high overall incidence of renal damage. Our population was one of the most seriously ill populations studied to date (average mortality, 25%), yet these patients were representative of the patients who most often require these agents and therefore deserved study. We found that gentamicin-treated and tobramycin-treated patients were at equal risk for renal damage. There were no clinical parameters unbalanced against the gentamicin-treated group, and thus we could not explain the greater occurrence of gentamicin nephrotoxicity on clinical grounds. On the contrary, the clinical differences which we did find between the gentamicin-treated and tobramycin-treated groups uniformly favored increased tobramycin nephrotoxicity. For Although there were no differences in dose or blood levels, the predominant pharmacokinetic difference between the gentamicin-treated and tobramycin-treated groups was an increased tissue accumulation in the gentamicin-treated group. Since our prospectively studied gentamicin-treated and tobramycin-treated groups did not differ in base-line risk factors or in risk factors developing during the treatment period, we propose that differences in the rates of renal damage resulted from differences in the tissue accumulation-related nephrotoxic potentials of gentamicin and tobramycin.
